FDA Issues Second Promethazine HCI Safety Alert
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency said it has received reports of seven deaths and 22 cases of respiratory depression in children under the age of two.
You may also be interested in...
Wyeth's Phenergan Contraindicated In Patients Under Two Years Of Age
Postmarketing adverse event reporting finds cases of fatal respiratory depression, revised labeling says. Wyeth informs physicians of the labeling change in a "Dear Doctor" letter.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.